[go: up one dir, main page]

MEP10609A - Nova anti-cd38 antitijela za tretman kancera - Google Patents

Nova anti-cd38 antitijela za tretman kancera

Info

Publication number
MEP10609A
MEP10609A MEP-106/09A MEP10609A MEP10609A ME P10609 A MEP10609 A ME P10609A ME P10609 A MEP10609 A ME P10609A ME P10609 A MEP10609 A ME P10609A
Authority
ME
Montenegro
Prior art keywords
cytotoxic
cell
conjugates
fragments
treatment
Prior art date
Application number
MEP-106/09A
Other languages
Bosnian (bs)
English (en)
Inventor
Peter U Park
Laura M Bartle
Anna Skaletskaya
Viktor S Golmakher
Daniel Tavares
Jutt A Deckert
Vincent Mikol
Veronique Blanc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP10609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MEP10609A publication Critical patent/MEP10609A/hr
Publication of ME00614B publication Critical patent/ME00614B/me

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
MEP-2009-106A 2006-10-19 2007-10-16 Nova anti-cd38 antitela za tretman kancera ME00614B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291628A EP1914242A1 (en) 2006-10-19 2006-10-19 Novel anti-CD38 antibodies for the treatment of cancer
PCT/IB2007/004172 WO2008047242A2 (en) 2006-10-19 2007-10-16 Novel anti-cd38 antibodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
MEP10609A true MEP10609A (hr) 2011-12-20
ME00614B ME00614B (me) 2011-12-20

Family

ID=37831721

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-106A ME00614B (me) 2006-10-19 2007-10-16 Nova anti-cd38 antitela za tretman kancera

Country Status (45)

Country Link
US (5) US8153765B2 (hr)
EP (4) EP1914242A1 (hr)
JP (2) JP5607364B2 (hr)
KR (5) KR101534452B1 (hr)
CN (1) CN101616933B (hr)
AR (1) AR063488A1 (hr)
AU (1) AU2007311511C1 (hr)
BR (1) BRPI0718130B1 (hr)
CA (2) CA2663209C (hr)
CL (3) CL2007002995A1 (hr)
CO (1) CO6190555A2 (hr)
CR (1) CR10679A (hr)
CY (2) CY1122302T1 (hr)
DK (1) DK2076540T3 (hr)
DO (1) DOP2017000177A (hr)
EA (1) EA025215B1 (hr)
ES (1) ES2726754T3 (hr)
FR (1) FR20C1061I2 (hr)
GT (1) GT200900079A (hr)
HK (1) HK1139956A1 (hr)
HR (1) HRP20190742T1 (hr)
HU (2) HUE043351T2 (hr)
IL (1) IL197217B (hr)
LT (2) LT2076540T (hr)
MA (1) MA30895B1 (hr)
ME (1) ME00614B (hr)
MX (1) MX2009004050A (hr)
MY (1) MY159374A (hr)
NL (1) NL301077I2 (hr)
NO (3) NO345911B1 (hr)
NZ (1) NZ575188A (hr)
PE (1) PE20081171A1 (hr)
PH (1) PH12012502467A1 (hr)
PL (1) PL2076540T3 (hr)
PT (1) PT2076540T (hr)
RS (1) RS58716B1 (hr)
SG (4) SG10201501733QA (hr)
SI (1) SI2076540T1 (hr)
SV (1) SV2009003203A (hr)
TN (1) TN2009000058A1 (hr)
TW (4) TWI609884B (hr)
UA (1) UA114879C2 (hr)
UY (1) UY30655A1 (hr)
WO (1) WO2008047242A2 (hr)
ZA (1) ZA200901395B (hr)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
WO2006122355A1 (en) * 2005-05-16 2006-11-23 Qrsciences Pty Ltd A system and method for improving the analysis of chemical substances using nqr
US9180149B2 (en) 2005-09-07 2015-11-10 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
CN103347393A (zh) 2009-09-14 2013-10-09 杰能斯有限公司 溶瘤牛痘病毒组合癌症疗法
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
AU2010335282B2 (en) 2009-12-22 2015-05-21 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
PL2516465T3 (pl) * 2009-12-23 2016-11-30 Przeciwciała anty-bv8 i ich zastosowania
US9220743B2 (en) * 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
EP2789622B1 (en) 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
CN103118706B (zh) 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP2661278B1 (en) * 2011-01-04 2019-06-19 SillaJen Biotherapeutics, Inc. Tumor specific complement dependent cytotoxicity (cdc) antibodies generated by administration of oncolytic vaccinia virus, for use in the treatment of cancer
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
US8795673B2 (en) 2011-03-29 2014-08-05 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
RU2013151599A (ru) 2011-04-21 2015-05-27 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение-активное соединение (adc) и их применение
JP6125489B2 (ja) * 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
JP6170494B2 (ja) 2011-09-20 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
AU2012322932B2 (en) 2011-10-14 2016-11-10 Medimmune Limited Pyrrolobenzodiazepines
ES2687246T3 (es) 2011-10-14 2018-10-24 Seattle Genetics, Inc. Pirrolobenzodiazepinas y conjugados dirigidos
EP3309162A1 (en) 2011-10-14 2018-04-18 Seattle Genetics, Inc. Targeted conjugates of pyrrolobenzodiazepines
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013075740A1 (en) * 2011-11-23 2013-05-30 Sanofi Antibody purification method
CA2864092C (en) * 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CN104470544B (zh) 2012-05-01 2018-01-12 基因泰克公司 抗pmel17抗体和免疫缀合物
CA2873889A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Anti-cd22 antibodies and immunoconjugates
ES2643225T3 (es) 2012-07-09 2017-11-21 Genentech, Inc. Inmunoconjugados que comprenden anticuerpos anti-CD79b
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
RU2650618C2 (ru) 2012-09-25 2018-04-16 МорфоСис АГ Комбинации и их применение
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
MX364327B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
US9415117B2 (en) 2012-10-12 2016-08-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
EP2914302B1 (en) 2012-11-05 2017-01-04 MorphoSys AG Radiolabelled antibody and uses thereof
US9624308B2 (en) 2012-11-05 2017-04-18 Pierre Fabre Medicament Antigen binding proteins
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN105407921A (zh) * 2013-03-13 2016-03-16 赛诺菲 包含抗cd38抗体和卡非佐米的组合物
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2014159835A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
NO2994485T3 (hr) * 2013-05-06 2018-06-09
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2016003248A (es) 2013-09-17 2016-06-07 Genentech Inc Metodos de uso de anticuerpos anti-lgr5.
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
PL3063173T3 (pl) * 2013-10-31 2021-01-11 Sanofi Swoiste przeciwciała anty-cd38 do leczenia nowotworów u ludzi
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
JP6721507B2 (ja) 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
JP2017506640A (ja) * 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
RU2714258C2 (ru) 2014-02-14 2020-02-13 Селлектис Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2946662A1 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
CN113134095A (zh) 2014-06-16 2021-07-20 梅约医学教育与研究基金会 治疗骨髓瘤
WO2015195556A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EP4074735A1 (en) 2014-08-28 2022-10-19 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
MX2017003115A (es) * 2014-09-09 2017-11-17 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38.
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
EA201790569A1 (ru) 2014-09-12 2017-08-31 Дженентек, Инк. Антитела и иммуноконъюгаты против cll-1
US9518118B2 (en) 2014-09-12 2016-12-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2957491A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
MX2017003472A (es) 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
WO2016083468A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN113735976A (zh) 2014-11-26 2021-12-03 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
BR112017011749A2 (pt) * 2014-12-04 2018-05-15 Janssen Biotech Inc anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
KR20180018808A (ko) 2015-06-22 2018-02-21 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) 및 항체 전구약물 접합체 (apdc)
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
US11078286B2 (en) 2015-09-20 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
DK3370770T3 (da) 2015-11-03 2021-03-01 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN105837688B (zh) * 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
KR20180083944A (ko) 2015-12-02 2018-07-23 아게누스 인코포레이티드 항체 및 이의 사용 방법
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
CN108778327B (zh) * 2016-01-09 2021-11-05 嘉立医疗科技(广州)有限公司 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
MA47022A (fr) 2016-02-05 2018-12-12 Immunogen Inc Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
IL260750B2 (en) 2016-03-04 2024-02-01 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CN108883195A (zh) 2016-03-24 2018-11-23 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20200087875A (ko) 2016-04-15 2020-07-21 바이오아트라, 엘엘씨 항 Axl항체 및 이의 면역접합체와 이것들의 용도
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
KR20180137517A (ko) 2016-05-13 2018-12-27 바이오아트라, 엘엘씨 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3474895A1 (en) 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
CN117330747A (zh) 2016-07-15 2024-01-02 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
CN110087673A (zh) 2016-07-19 2019-08-02 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
US10478497B2 (en) * 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
WO2018026533A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
KR20190053203A (ko) 2016-09-01 2019-05-17 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｔ－세포 암을 표적화하는 방법 및 조성물
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
AU2017324335A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2018224685A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
CA3067311A1 (en) 2017-06-20 2018-12-27 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
JP7370958B2 (ja) 2017-07-31 2023-10-30 アクティニウム ファーマシューティカルズ インコーポレイテッド 血液悪性腫瘍の治療
EP4296680A3 (en) * 2017-08-10 2024-03-20 Grifols Diagnostic Solutions Inc. An oligomerization tag comprising an immunoglobulin fc region and a polyhis domain
EP3668896A1 (en) * 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 modulating antibody
EP3668543A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
CA3075399A1 (en) 2017-09-13 2019-03-21 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN116999572A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
CN111183157A (zh) 2017-10-02 2020-05-19 威特拉公司 Cd138抗体分子及其用途
KR20200061402A (ko) * 2017-10-10 2020-06-02 사노피 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AU2018360800B2 (en) 2017-11-01 2024-11-21 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
ES2971659T3 (es) 2017-11-01 2024-06-06 Juno Therapeutics Inc Procedimiento para la producción de una composición de células T
US20230132400A9 (en) * 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
JP2021505168A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 操作されたｔ細胞の組成物を製造するための方法
EP3720949A1 (en) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
SG11202005217VA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Phenotypic markers for cell therapy and related methods
EP3694546A1 (en) 2018-01-30 2020-08-19 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
BR112020015479A2 (pt) * 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
MA52640A (fr) 2018-05-16 2021-03-24 Janssen Biotech Inc Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途
TW202019962A (zh) 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
EP3833759A1 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
CN112513087B (zh) * 2018-09-11 2023-01-24 江苏恒瑞医药股份有限公司 抗cd38抗体、其抗原结合片段及医药用途
CN109293773B (zh) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 靶向cd38蛋白的抗体、嵌合抗原受体和药物
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN113195540A (zh) 2018-10-17 2021-07-30 詹森生物科技公司 提供皮下施用抗cd38抗体的方法
JP2022505445A (ja) 2018-10-26 2022-01-14 テネオバイオ， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
BR112021008289A2 (pt) 2018-11-01 2021-10-26 Juno Therapeutics, Inc. Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
CN113015805B (zh) 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
JP7608334B2 (ja) * 2018-12-14 2025-01-06 モルフォシス・アーゲー 抗体製剤
EP3883608A1 (en) 2019-01-08 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2022523710A (ja) * 2019-01-28 2022-04-26 マルチチュード インコーポレーテッド Ｃｄ４４に特異的な抗体
US11939390B2 (en) 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
MX2021010313A (es) 2019-02-27 2021-09-23 Genentech Inc Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
CN113574071A (zh) 2019-03-15 2021-10-29 莫佛塞斯公司 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
MA55761A (fr) * 2019-04-23 2022-03-02 Sanofi Sa Formulations et anticorps anti-cd38
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
JP2022531222A (ja) 2019-05-01 2022-07-06 ジュノー セラピューティクス インコーポレイテッド 改変されたｔｇｆｂｒ２遺伝子座から組換え受容体を発現する細胞、関連ポリヌクレオチド、および方法
US20210171650A1 (en) 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022000016A (es) 2019-06-27 2022-02-24 Crispr Therapeutics Ag Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
MX2022000922A (es) 2019-07-23 2022-05-03 Mnemo Therapeutics Celulas inmunes defectuosas para suv39h1.
CN112538114A (zh) * 2019-09-20 2021-03-23 上海普铭生物科技有限公司 抗人cd38抗体及其应用
AU2020371628A1 (en) * 2019-10-21 2022-05-19 Purdue Research Foundation Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
EP4031250A1 (en) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
WO2021113739A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
EP4069740A1 (en) * 2019-12-06 2022-10-12 Sanofi-Aventis U.S. LLC Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma
US20230032465A1 (en) 2019-12-12 2023-02-02 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for cd276 and uses thereof
EP4077391A1 (en) 2019-12-18 2022-10-26 Teneofour, Inc. Heavy chain antibodies binding to cd38
JP2023510397A (ja) 2020-01-16 2023-03-13 ジェンマブ エー／エス Ｃｄ３８抗体の製剤およびその使用
IL297147A (en) 2020-04-10 2022-12-01 Juno Therapeutics Inc Methods and Uses Related to Transgenic Cell Therapy with a Chimeric Antigen Receptor Directed to a B-Cell Maturation Antigen
KR20230005268A (ko) * 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
EP4211244A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
WO2022099257A1 (en) 2020-11-03 2022-05-12 Sanofi-Aventis U.S. Llc Use of isatuximab for the treatment of multiple myeloma
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
US20240003879A1 (en) 2020-11-27 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
KR20230142834A (ko) 2021-01-14 2023-10-11 모르포시스 아게 항-cd38 항체 및 이의 용도
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
EP4301755A1 (en) 2021-03-03 2024-01-10 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4337763A1 (en) 2021-05-10 2024-03-20 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
CN113244175B (zh) * 2021-05-22 2022-11-04 苏州大学 一种免疫囊泡美登素偶联物及其制备方法与应用
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
CA3216228A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
MX2024001211A (es) 2021-07-28 2024-02-12 Genentech Inc Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre.
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
JP2024540054A (ja) 2021-11-03 2024-10-31 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法
CA3237175A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
CN113912727B (zh) * 2021-11-16 2023-05-02 福州迈新生物技术开发有限公司 抗cd38蛋白单克隆抗体、细胞系及其制备方法和应用
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
CN114457017B (zh) * 2022-01-19 2023-10-17 四川大学华西第二医院 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4479431A1 (en) 2022-02-18 2024-12-25 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
AU2023231217A1 (en) 2022-03-07 2024-10-17 Sanofi-Aventis U.S. Llc Use of isatuximab in combination with other agents for the treatment of multiple myeloma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US2429004A (en) 1947-02-20 1947-10-14 Wachsman Michael Fabric contacting circuit closer for knitting machines
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) * 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) * 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP3105898B2 (ja) 1988-04-16 2000-11-06 セルテック リミテッド 組換えｄｎａタンパクの製造方法
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
JPH06511156A (ja) * 1992-07-16 1994-12-15 イコス　コーポレイション 炎症性疾患状態に関連する症状の緩和
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2384942T3 (es) 1996-12-03 2012-07-16 Amgen Fremont Inc. Anticuerpos humanos que se unen específicamente al TNF alfa
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
PT1193270E (pt) 1998-08-27 2003-10-31 Spirogen Ltd Pirrolobenzodiazepinas
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PT1242401E (pt) 1999-11-24 2007-03-30 Immunogen Inc Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico
NZ518764A (en) * 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
BR0114475A (pt) 2000-10-06 2003-12-23 Kyowa Hakko Kogyo Kk Célula para a produção de composição de anticorpo
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP4580340B2 (ja) 2002-09-27 2010-11-10 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2003295411A1 (en) * 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
PT1578446E (pt) 2002-11-07 2015-07-22 Immunogen Inc Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
US20050208627A1 (en) * 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
JPWO2005035741A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
EP1720907B1 (en) * 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
JP4633788B2 (ja) * 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
JP5848861B2 (ja) * 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2571404A1 (en) * 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants
EP2412728B1 (en) * 2004-08-03 2015-01-07 Innate Pharma Therapeutic compositions against cancer targeting 4IG-B7-H3
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
ZA200709003B (en) * 2005-03-23 2009-05-27 Genmab As Antibodies against CD38 for treatment of multiple myeloma
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
TW200745162A (en) * 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
DE102005030112A1 (de) 2005-06-28 2007-01-18 Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH Lötzusatzwerkstoff
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
RS52060B (en) 2006-01-25 2012-04-30 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2731255C (en) 2008-07-21 2018-06-05 David M. Goldenberg Structural variants of antibodies for improved therapeutic characteristics
CN103118706B (zh) * 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
NZ756727A (en) * 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
EP2819089A4 (en) 2012-02-20 2015-09-23 Knowre Korea Inc METHOD AND SYSTEM FOR PROVIDING EDUCATIONAL SERVICES BASED ON A KNOWLEDGE UNIT AND A COMPUTER READABLE RECORDING MEDIUM
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
MX2017003115A (es) * 2014-09-09 2017-11-17 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38.
BR112017011749A2 (pt) * 2014-12-04 2018-05-15 Janssen Biotech Inc anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda
US11119960B2 (en) * 2015-01-06 2021-09-14 Hewlett-Packard Development Company, L.P. Adapter to concatenate connectors
MY198983A (en) * 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
US10668149B2 (en) * 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3370770T3 (da) * 2015-11-03 2021-03-01 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) * 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
KR20200061402A (ko) * 2017-10-10 2020-06-02 사노피 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Also Published As

Publication number Publication date
KR20150023010A (ko) 2015-03-04
GT200900079A (es) 2010-07-09
TW201518322A (zh) 2015-05-16
ES2726754T3 (es) 2019-10-09
PH12012502467A1 (en) 2013-06-17
JP2014221761A (ja) 2014-11-27
MA30895B1 (fr) 2009-11-02
SG173345A1 (en) 2011-08-29
UY30655A1 (es) 2008-05-31
DK2076540T3 (da) 2019-05-13
AU2007311511B9 (en) 2020-11-12
TN2009000058A1 (en) 2010-08-19
US20120156218A1 (en) 2012-06-21
NO345911B1 (no) 2021-10-11
CY2020039I2 (el) 2021-05-05
KR20140105035A (ko) 2014-08-29
HK1139956A1 (en) 2010-09-30
KR101534452B1 (ko) 2015-07-06
NL301077I1 (hr) 2020-12-02
WO2008047242A3 (en) 2008-06-26
EP1914242A1 (en) 2008-04-23
NO2021044I1 (no) 2021-10-13
EA200970393A1 (ru) 2009-12-30
ZA200901395B (en) 2010-06-30
MX2009004050A (es) 2009-04-28
CN101616933A (zh) 2009-12-30
ME00614B (me) 2011-12-20
AU2007311511B2 (en) 2013-08-22
TWI609884B (zh) 2018-01-01
PT2076540T (pt) 2019-06-06
CL2012002012A1 (es) 2012-11-05
PL2076540T3 (pl) 2019-08-30
US20200408765A1 (en) 2020-12-31
EP2076540B1 (en) 2019-02-27
PE20081171A1 (es) 2008-09-26
JP2010506582A (ja) 2010-03-04
WO2008047242A9 (en) 2009-02-05
IL197217B (en) 2019-12-31
CL2007002995A1 (es) 2008-05-16
KR20170129960A (ko) 2017-11-27
AU2007311511C1 (en) 2021-11-04
LT2076540T (lt) 2019-06-10
TWI609885B (zh) 2018-01-01
AU2007311511A1 (en) 2008-04-24
TW201734053A (zh) 2017-10-01
FR20C1061I2 (fr) 2022-02-11
US20170343550A1 (en) 2017-11-30
EP3498735A1 (en) 2019-06-19
AR063488A1 (es) 2009-01-28
SV2009003203A (es) 2009-10-27
UA114879C2 (uk) 2017-08-28
EP2076540A2 (en) 2009-07-08
CA2663209C (en) 2018-02-13
CY1122302T1 (el) 2021-01-27
EA025215B1 (ru) 2016-12-30
SI2076540T1 (sl) 2019-06-28
BRPI0718130A2 (pt) 2013-11-05
WO2008047242A8 (en) 2009-08-06
NO20091712L (no) 2009-05-13
WO2008047242A2 (en) 2008-04-24
MY159374A (en) 2016-12-30
US20110262454A1 (en) 2011-10-27
CN101616933B (zh) 2015-06-10
TWI538917B (zh) 2016-06-21
US20090304710A1 (en) 2009-12-10
KR20150119976A (ko) 2015-10-26
CR10679A (es) 2009-06-24
NL301077I2 (nl) 2021-02-03
SG10202012950TA (en) 2021-02-25
TW200823236A (en) 2008-06-01
CL2017001580A1 (es) 2018-03-02
HUS2000048I1 (hu) 2020-12-28
JP6121366B2 (ja) 2017-04-26
CA2663209A1 (en) 2008-04-24
FR20C1061I1 (hr) 2021-01-22
CA2989609A1 (en) 2008-04-24
BRPI0718130B1 (pt) 2022-05-03
CY2020039I1 (el) 2021-03-12
NO20211026A1 (no) 2009-05-13
SG10201501733QA (en) 2015-04-29
DOP2017000177A (es) 2017-09-15
NO348288B1 (no) 2024-11-11
TW201630938A (zh) 2016-09-01
RS58716B1 (sr) 2019-06-28
IL197217A0 (en) 2011-08-01
US8153765B2 (en) 2012-04-10
NZ575188A (en) 2012-07-27
KR101852317B1 (ko) 2018-04-25
EP3909980A1 (en) 2021-11-17
HRP20190742T1 (hr) 2019-06-14
LTPA2020536I1 (lt) 2020-12-28
KR101800328B1 (ko) 2017-11-22
CO6190555A2 (es) 2010-08-19
JP5607364B2 (ja) 2014-10-15
SG174777A1 (en) 2011-10-28
KR20090078330A (ko) 2009-07-17
HUE043351T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
MEP10609A (hr) Nova anti-cd38 antitijela za tretman kancera
van Bueren et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.
ME02369B (me) Antitela za terapiju kancera koji eksprimira klaudin 6
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
EA201000910A1 (ru) Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
EP4234581A3 (en) Therapeutic antibodies and their uses
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
SG170080A1 (en) Human monoclonal antibodies to o8e
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
PH12013502043A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
JP2010110329A5 (hr)
MY192146A (en) Binding molecules specific for asct2 and uses thereof
MX343376B (es) Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados.
PH12019500482A1 (en) Antibody for treating autoimmune diseases
Qi et al. A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2024206439A3 (en) Antibodies and chimeric antigen receptors specific for cd38
Aud et al. MEN1112, a novel humanized de-fucosylated monoclonal antibody with high affinity and specificity for Bst1/CD157 antigen and enhanced CD16 binding
TH104651B (th) แอนติบอดีต่อต้าน-cd38 ชนิดใหม่สำหรับการรักษามะเร็ง